Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IAE0972 + Chemotherapy in R/M HNSCC/NPC
NCT06719479Phase 3Not yet recruiting
- Sponsor
- SUNHO BioPharmaceutical
- Start
- Jan 2025
- Primary completion
- Jan 2028
- Modality
- Immunomodulatory ADCs, Fc Fusion Proteins
01
Overview
Phase 3, randomised, double-blind trial of IAE0972 in head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal carcinoma (NPC) (5 arms), sponsored by SUNHO BioPharmaceutical. Primary endpoint: Treatment-related adverse events up to 2 years. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
IAE0972
03
Conditions
head and neck squamous cell carcinoma (HNSCC)nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06719479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06719479.